NEURAL REGENERATION RESEARCH, 2022 · DOI: 10.4103/1673-5374.335830 · Published: October 1, 2022
Injuries to the central nervous system (CNS) often result in permanent disabilities because adult CNS neurons exhibit limited axon regeneration. The brain has an intrinsic capability of recovering itself after injury. The mechanistic target of rapamycin (mTOR) signaling is one of the most crucial intrinsic regenerative pathways that drive axonal regeneration and sprouting in various CNS injuries. RNA-based therapeutics are suitable for blocking key mTOR signaling components such as phosphatase and tensin homolog (PTEN) and have attracted substantial attention recently.
Identifies mTOR pathway, particularly PTEN, as a promising therapeutic target for promoting axon regeneration after CNS injuries.
Highlights the potential of RNA-based therapeutics, such as antisense oligonucleotides, for modulating mTOR signaling components to enhance neural repair.
Emphasizes the importance of developing effective brain-targeted drug delivery systems, including nanoparticle technology, to facilitate clinical application of RNA-based therapies.